Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
Conclusion: Pazopanib is a promising therapeutic option in patients with HEH.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Hemangioendothelioma | Liver | Sarcomas | Study | Urology & Nephrology | Women